Wockhardt gets US FDA nod for launching Azithoromycin

Ahmedabad, Feb 13 (UNI) Pharmaceutical and biotechnology major Wockhardt received approval from the United States Food and Drug Administration (US FDA) for marketing the tablets Azithromycin, used for treating various kinds of infections.

Wockhardt is only one of the four companies to have received this approval, said Wockhardt Chairman Habil Khorakiwala.

''Development of Azithromycin is a reflection of Wockhardt's strong R&D for bulk drugs and formulations. This again is a proof of Wockhardt's commitment and dedication to develop innovative technologies, to capture opportunities in the USA,'' said Mr Khorakiwala.

The Chairman further informed, Wockhardt's Azithromycin which is used in treating several kinds of infections and is one of the most potent, powerful and safe antobiotics tablets will be launched in the US market immediately. Wockhardt today markets over fifty products in the US, the Chairman added.

The Azithromycin API is manufactured in the FDA approved API facility at Ankleshwar in Gujarat and the tablets are manufactured at the US FDA certified formulation plant at Aurangabad, Maharashtra.

Wockhardt is one of the few companies with end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's and marketing through the wholly-owned subsidiary in the US, enabling the company to capture maximum value, sources said.

UNI PVN DB BJR BD1728